Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled study of ligelizumab in peanut allergy
jRCT2031210532Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in peanut allergy comparing Ligelizumab 240 mg with Placebo (2 arms). Started Mar 2022; status: completed.
02
Drugs
ligelizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on jRCT2031210532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210532.